IGF-I GENERATION TEST IN CHILDREN WITH CHRONIC KIDNEY FAILURE

慢性肾功能衰竭儿童的 IGF-I 生成测试

• 批准号: 7379430
• 负责人: SANDRA L. WATKINS
• 金额: $ 0.5万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379430
• 关键词: IGF; GENERATION; TEST; CHILDREN; CHRONIC

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the research study is to examine the growth hormone (GH) responsiveness in children with chronic kidney disease (CKD) who are exhibiting growth retardation. Growth retardation is a common condition in children with CKD and is thought to be caused predominantly by disturbances of the growth hormone-insulin-like growth factor (GH/IGF-I) axis. The hypothesis of the study is that measuring IGF-I concentrations produced in response to different doses of exogenous growth hormone therapy will allow the prediction of growth hormone responsiveness and consequently enable growth hormone doses to be tailored for each individual. This is a multi-center, prospective, randomized, open label, pilot study. Thirty participants with chronic kidney disease and short stature or poor growth velocity will be enrolled and will receive study treatment for 56 weeks following an 8 week observation period (64 week total study duration).

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。该研究的目的是检查患有慢性肾病 (CKD) 且表现出生长迟缓的儿童的生长激素 (GH) 反应性。生长迟缓是 CKD 儿童的常见病症，被认为主要是由生长激素-胰岛素样生长因子 (GH/IGF-I) 轴紊乱引起的。该研究的假设是，测量不同剂量的外源生长激素治疗产生的 IGF-I 浓度将能够预测生长激素的反应性，从而能够为每个人量身定制生长激素剂量。这是一项多中心、前瞻性、随机、开放标签的试点研究。将招募 30 名患有慢性肾病、身材矮小或生长速度慢的参与者，并在 8 周观察期（总研究持续时间 64 周）后接受为期 56 周的研究治疗。